Publications
Publications
Since the launch of PRIMA July 2023, 50 papers have been published in peer reviewed international journals. (19 in 2023 and 32 in 2024). Among these, 65% of the papers are published in journals with Impact Factor (IF) above 5, and 18% of the papers are results of collaborations between two or more PRIMA groups.
Impact factor
- Mean: 9.1
- Median: 5.9
of the publications have IF>5
of the publications have international collaborators
are collaborations within PRIMA
Media publications
Media coverage
Our scientists have been 18 times in national and international public media, presenting the research in PRIMA to the public (as of Sept 2024).
Lectures and presentations
Dissemination
Centre researchers have 66 times been invited speakers at international and national conferences. Our research have been presented all around the world in a total of 125 times (as of Sept 2024).
Education
Two PhD students defended their PhD thesis in 2023, and three in 2024. The very successful candidates are listed below.
Seven MSc degrees
- Siv Skundberg Jensen
- Eystein Lie Asdal
- Janaarthan Ganeshan
- Alonso Sanchez
- Clementine Ingrid Sey
- Irene Alonso Cabanas
- Kasper Melchers
PhD degrees
PhD
Kathrine Thuestad Isaksen, 2023
Age-related and molecular predictive markers in diffuse large B-cell lymphoma
PhD
Alvaro Haroun-Izquierdo, 2023
Natural killer cell development and function in the context of allogenic stem cell transplantation and cell therapy
PhD
Julia Heinzelbecker, 2024
Novel strategies for manipulation of T-cell effector functions in cancer treatment
PhD
Dennis Clement, 2024
Molecular regulation of Natural Killer Cell function – role of Ca2+ signalling from the secretory lysosome
PhD
Kristin Hovden Aaen, 2024
Next-generation human albumin fusion proteins engineered for enhanced plasma half-life and therapeutic efficacy
Total funding
PRIMA is funded by a Centre of Excellence grant from the Research Council of Norway (RCN), own financing from UiO and OUS, and from other external funding bodies.
million NOK in 2023
(from launch date July 1)
million NOK in 2024
Other external funding
PRIMA's external funding is mainly sourced from national entities, such as other RCN grants, the South-Eastern Norway Regional Health Authority, and the Norwegian Cancer Society. Additionally, 21% of PRIMA's external funding comes from international sources, including organizations like NIH, CRUK, the EU, CEPI, and various industry collaborations.